According to The World Health Organization (WHO), one in four people in the world will be affected by mental or neurological disorders at some point in their lives.
The COVID-19 pandemic has exacerbated mental health issues and heightened anxiety and triggered new conditions for people already suffering from mental illnesses and substance abuse. Thus, it is timely and empirical to explore new approaches and possibilities to treat these conditions even more so.
Biotech startup Cybin Inc. (NEO: CYBN, OTCQB: CLXPF), a company that is advancing psychedelic therapeutics, recently announced its plans to leverage a budding partnership with Kernel to utilize the latter company’s Flow device to quantify brain activity during psychedelic experiences in real-time. This mutually beneficial partnership adds an exciting dimension to Cybin’s investigative work focusing on developing breakthrough therapeutics for mental health disorders.
About Kernel Flow
Kernel Flow is a non-invasive brain interface that records real-time cortical hemodynamics to establish precise patterns of brain activity. Hemodynamic response (HR) allows the rapid delivery of blood to active neuronal tissues. The brain consumes significant amounts of energy but does not have a reservoir of stored energy substrates.
“The real benefit of Flow is its portability and miniaturization. Other decent neuroimaging technologies exist today. However, the patient access that can be made possible from Flow’s portability can enable us to collect data on a much more frequent and longitudinal basis, providing a larger, more significant, and more valuable data set,” says Doug Drysdale, CEO of Cybin.
Kernel’s whole head coverage brain interface connects easily via USB-C and features: 1000+ Source detector pairs, 690nm – 850nm Wavelengths, and 200 Hz Sampling frequency.
“The ability to collect quantitative data from our sponsored drug development programs with Kernel’s Flow is potentially game-changing in terms of our ability to measure where psychedelics work in the brain in real-time and how we ultimately design our future therapeutics. This is a new cornerstone component of our sponsored clinical programs,” says Drysdale.
“Cybin’s visionary approach to understanding and treating mental illness through psychedelic pharmaceutical therapies opens a new frontier for addressing human health and wellness. This opportunity with Cybin will assist the transition from subjective self-reporting to longitudinal, quantitative measurements and insights, thereby offering the promise of data-driven, personalized treatment protocols that may significantly improve safety and efficacy,” says Bryan Johnson, Founder and CEO of Kernel.
